BriaCell Therapeutics Corp 6-K, filed May 20, 2021
BriaCell Therapeutics Corp. (BCTX)
About this 6-K
BriaCell Therapeutics Corp filed this 6-K on May 20, 2021.
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM6-K
REPORTOF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2021
Commission File Number: 001-40101
BRIACELLTHERAPEUTICS CORP.
(Translation of registrant’s name into English)
Suite300 – 235 15^th^ Street
WestVancouver, BC V7T 2X1
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [X] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]
BRIACELLTHERAPEUTICS CORP.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BriaCell Therapeutics Corp. | ||
|---|---|---|
| Date:<br> May 19, 2021 | By: | /s/ William V. Williams |
| Name: | William<br> V. Williams | |
| Title: | Chief<br> Executive Officer |
Exhibit99.1
BRIACELLTHERAPEUTICS CORP. ANNOUNCES RESULTS OF SHAREHOLDER MEETING
BERKELEY, Calif., and VANCOUVER, British Columbia, May 19, 2021 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell”or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “Shareholders”) for the years ended July 31, 2019 and July 31, 2020 held on May 18, 2021 (the “Meeting”). A total of 1,685,180 common shares of the Company (the “Common Shares”) were voted, representing 22.36% of the Company’s issued and outstanding Common Shares. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions that consisted of the following:
| 1. | The<br> number of directors set at six; |
|---|---|
| 2. | Election<br> of Dr. William V. Williams, Mr. Jamieson Bondarenko, Dr. Charles Wiseman, Dr. Rebecca Taub,<br> Mr. Vaughn C. Embro-Pantalony, and Mr. Martin Schmieg as directors of the Company; |
| 3. | Appointment<br> of MNP LLP as auditors of the Company for the ensuing year and authorizing the directors<br> to fix their remuneration; |
| 4. | Renewal<br> of the Company’s stock option plan; |
| 5. | Ratification<br> of the number of directors set at six for the prior year ended July 31, 2019; |
| 6. | Ratification<br> of the election of Dr. William V. Williams, Mr. Jamieson Bondarenko, Mr. Richard Berman,<br> Mr. Vaughn C. Embro-Pantalony, Dr. Rebecca Taub, and Dr. Charles Wiseman as directors of<br> the Company for the prior year ended July 31, 2019; |
| 7. | Ratification<br> of the appointment of MNP LLP as the auditors of the Company for the prior year ended July<br> 31, 2019 and ratifying the directors authorization to fix their remuneration; |
| 8. | Ratification<br> of the Company’s stock option plan for the prior year ended July 31, 2019; and |
| 9. | Ratification<br> of holding the Company’s annual general and special meeting for the year ended July<br> 31, 2019 on May 18, 2021. |
Having received Shareholder approval, the Company’s stock option plan remains subject to approval from the TSX Venture Exchange. The formal report on voting results with respect to all maters voted upon during the Meeting will be filed on the Company’s SEDAR profile at www.sedar.com.
AboutBriaCell
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
For additional information on BriaCell, please visit: https://briacell.com/.
CautionaryNote Regarding Forward-Looking Information
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s SEC filings. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
ContactInformation
For further information, please contact:
CompanyContact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
MediaRelations:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
InvestorRelations Contact:
CORE IR
investors@briacell.com
Exhibit 99.2
BRIACELLTHERAPEUTICS COP. (the “Company”)
REPORT OF VOTING RESULTS
ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
HELD ON MAY 18, 2021
Section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations
The following is the Report on Voting for the Annual General and Special Meeting of the shareholders of the Company (“Shareholders”) held on Tuesday, May 18, 2021 (“Meeting”). All matters that were placed before the Shareholders for consideration at the Meeting were approved.
A total of 1,685,180 common shares of the Company (“Common Shares”) representing 22.36% of the Company’s issued and outstanding Common Shares were voted in connection with the Meeting.
| Outcome of Vote | Voting Results | ||||
|---|---|---|---|---|---|
| **** | Votes For | Votes Against | |||
| 1. | Setting the number of directors at six (6). | Carried | 300,257<br><br> <br>(97.82%) | 6,680<br><br> <br>(2.18%) | |
| Outcome of Vote | Votes For | Votes Withheld | |||
| 2. | The election of the following directors: | **** | **** | **** | |
| (a) | Dr. William V. Williams | Elected | 300,115<br><br> <br>(97.78%) | 6,822<br><br> <br>(2.22%) | |
| (b) | Mr. Jamieson Bondarenko | Elected | 296,090<br><br> <br>(96.47%) | 10,847<br><br> <br>(3.53%) | |
| (c) | Dr. Charles Wiseman | Elected | 296,047<br><br> <br>(96.45%) | 10,890<br><br> <br>(3.55%) | |
| (d) | Dr. Rebecca Taub | Elected | 300,552<br><br> <br>(97.92%) | 6,385<br><br> <br>(2.08%) | |
| (e) | Mr. Vaughn C. Embro-Pantalony | Elected | 299,438<br><br> <br>(97.56%) | 7,499<br><br> <br>(2.44%) | |
| (f) | Mr. Martin Schmieg | Elected | 301,045<br><br> <br>(98.08%) | 5,892<br><br> <br>(1.92%) | |
| Outcome of Vote | Votes For | Votes Withheld | |||
| 3. | Appointment of MNP LLP, as auditors of the Company and authorizing the directors to fix their remuneration. | Carried | 1,652,928<br><br> <br>(98.09%) | 32,252<br><br> <br>(1.91%) | |
| Outcome of Vote | Votes For | Votes Against | |||
| 4. | Renewal of Stock Option Plan. | Carried | 252,968<br><br> <br>(82.42%) | 53,969<br><br> <br>(17.58%) | |
| Outcome of Vote | Votes For | Votes Against | |||
| 5. | Ratification of Setting the Number of Directors at 6 for the prior year ended July 31, 2019. | Carried | 297,684<br><br> <br>(96.99%) | 9,253<br><br> <br>(3.01%) | |
| Outcome of Vote | Votes For | Votes Against | |||
| 6. | Ratification of the election of Dr. William V. Williams, Mr. Jamieson Bondarenko, Mr. Richard Berman, Mr. Vaughn C. Embro-Pantalony, Dr. Rebecca Taub, and Dr. Charles Wiseman as directors of the Company for the prior year ended July 31, 2019. | Carried | 287,569<br><br> <br>(93.69%) | 19,368<br><br> <br>(6.31%) | |
| Outcome of Vote | Votes For | Votes Against | |||
| 7. | Ratification of the appointment of MNP LLP, as auditors of the Company for the prior year ended July 31, 2019 and authorizing the directors to fix their remuneration for the prior year ended July 31, 2019. | Carried | 301,781<br><br> <br>(98.32%) | 5,156<br><br> <br>(1.68%) | |
| Outcome of Vote | Votes For | Votes Against | |||
| 8. | Ratification of the renewal of the Company’s Stock Option Plan for the prior year ended July 31, 2019. | Carried | 250,487<br><br> <br>(81.61%) | 56,450<br><br> <br>(18.39%) | |
| Outcome of Vote | Votes For | Votes Against | |||
| 9. | Ratification of holding the annual general and special meeting of the Shareholders for the year ended July 31, 2019 on May 18, 2021. | Carried | 302,282<br><br> <br>(98.48%) | 4,655<br><br> <br>(1.52%) |